Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.93 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | PARP1 | P09874 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505469 | 0.85 | HSD17B10 (0.69) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL19984708 | 0.84 | HSD17B10 (0.67) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL30857592 | 0.83 | HSD17B10 (0.72) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL29114224 | 0.81 | HSD17B10 (0.69) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL25667529 | 0.80 | HSD17B10 (0.71) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL713441 | 0.80 | HSD17B10 (0.61) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL708632 | 0.80 | HSD17B10 (0.61) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL29114176 | 0.79 | HSD17B10 (0.66) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL19984617 | 0.79 | HTT (0.62) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 | |
| SCHEMBL19984555 | 0.79 | ALOX15 (0.60) | HSD17B10ALOX15L3MBTL1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421763-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086777-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9738659-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738659-B2 | Compositions of protein receptor tyrosine kinase inhibitors | PURDUE PHARMA L.P. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-9040508-B2 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040508-B2 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-8809530-B1 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809530-B1 | Compositions of protein receptor tyrosine kinase inhibitors | VM PHARMA LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. | 2014-08-14 | — | — | US | disclosed |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | PURDUE PHARMA L.P. | 2014-08-14 | — | — | US | disclosed |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM PHARMA LLC (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2376495-A2 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM Pharma LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077680-A2 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM DISCOVERY INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077680-A2 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | VM DISCOVERY INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218188-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | HSD17B10 4347/4885ALOX15 4203/4885L3MBTL1 2925/4885 |
| US-10421763-B2 | Compositions of protein receptor tyrosine kinase inhibitors | NGFR, NGF, GRB2 | HSD17B10 4347/4885ALOX15 4203/4885L3MBTL1 2925/4885 |
| US-20140228331-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | HSD17B10 4347/4885ALOX15 4203/4885L3MBTL1 2925/4885 |
| US-20180086777-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | HSD17B10 4395/4885ALOX15 4295/4885L3MBTL1 3041/4885 |
| US-20110301133-A1 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS | NGFR, NGF, GRB2 | HSD17B10 4347/4885ALOX15 4203/4885L3MBTL1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.